YMAB — Y-mAbs Therapeutics Share News
0.000.00%
Last trade - 00:00- $390.32m
- $328.02m
- $87.69m
Y-mAbs down as FDA declines to approve co's pediatric cancer drug
Brief: Y-mAbs Announces Complete Response Letter For Omburtamab Biologics License Application
U.S. FDA declines to approve Y-mAbs's pediatric cancer drug
Y-mAbs Therapeutics jumps after Q3 revenue tops estimates
Y-mAbs Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Y-mAbs Reports Third Quarter 2022 Financial Results, Recent Corporate Developments
Y-mAbs Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Jeld-Wen Holding, Apple, Emerson Electric
Y-mabs slumps as FDA panel vote against cancer drug drives PT cuts
U.S. RESEARCH ROUNDUP-Aveo Oncology, Gritstone Bio, Y-Mabs Therapeutics
Brief: Y-Mabs Announces Outcome Of FDA Advisory Committee Meeting On Omburtamab
Brief: Y-mAbs Announces Pivotal Data For Omburtamab
Brief: Y-mAbs Announces Regulatory Filing For DANYELZA (naxitamab-gqgk) In Brazil
Brief: Y-mAbs Announces Scheduling Of FDA Advisory Committee Meeting For Omburtamab
Y-mAbs Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Y-Mabs Announces Second Quarter Financial Results And Recent Corporate Developments
Brief: Y-mAbs Announces Clearance Of IND For GD2-SADA
U.S. STOCKS ON THE MOVE-Kirkland's, Snap, casino stocks